|
(Health-NewsWire.Net, December 15, 2021 ) The Research Report on “In Vivo Toxicology Market by Product (Animal Models, Reagents & Kits), Test Type (Chronic, Sub-acute), Toxicity Endpoints (Systemic, Immunotoxicity), Testing Facility (Outsourced, In-house), End User (Academic & Research Institute, CROs) – Forecast to 2025“, the global in vivo toxicology testing market size is projected to reach USD 6.6 billion by 2025, at a CAGR of 5.5% between 2020 and 2025.
Driver: Increasing pharmaceutical R&D activities;
Changing dynamics in the healthcare markets across the globe have compelled pharmaceutical and biotechnology companies to develop products that offer real value rather than just incremental benefits. Owing to this, an increasing number of pharma companies and medical device manufacturers focus on innovation and increasing their R&D efficiencies.
R&D activities, however, are associated with a high risk of failure. One estimate is that for every 10,000 compounds synthesized in the discovery phase, only 250 reach the preclinical phase, ultimately resulting in one approved drug by the FDA (Source: National Center for Biotechnology Information). Thus, it is very important to bring down the attrition of failing molecules in the early stages of drug development. The primary goal of R&D is to increase the overall likelihood of approval of Phase I candidates by increasing the acceptance of the compounds in the preclinical stages. To achieve this, intensive R&D is conducted in the early stages of drug development. Increased R&D investments in the initial stages of drug development are likely to increase the use of in vivo toxicology methods before the drug reaches the more expensive clinical stage.
According to the Biotechnology Industry Organization (BIO) 2019, nearly 82.7% of the venture capital investment in the US by emerging growth companies (EGCs) over the last decade was in R&D for emerging therapeutics and novel drugs. Likewise, ~50% of the venture capital investment for therapeutics was for developing biologic molecules/metabolites. Companies are also investing in research to develop breakthrough molecules/metabolites to cater to growing demands in the healthcare industry
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105308811
Industry Segmentation In Detailed:
The immunotoxicity segment accounted for the largest share of the in vivo toxicology market
Based on toxicity endpoint, segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental & reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). In 2019, the immunotoxicity segment accounted for the largest share of the global in vivo toxicology testing market, followed by the systemic toxicity segment.The rising demand for the development of biologics and biosimilars is driving the growth of the immunotoxicity segment
The chronic test type segment accounted for the largest share of the in vivo toxicology market
Based on test type, segmented into acute, sub-acute, sub-chronic, and chronic test type. The chronic test type segment is expected to dominate the market during the forecast period. In 2019, the chronic test type segment held the largest share of the market, followed by sub-chronic test type.Increasing research on drugs used for longer-duration therapy such as anti-cancer, anti-convulsive, anti-arthritis, and anti-hypertensives drives the growth of the chronic test type market.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=105308811
Leading Key Players and Analysis:
The major players operating in In Vivo Toxicology Market are by Charles River Laboratories (US), The Jackson Laboratory (US), Envigo (US), Taconic Biosciences, Inc. (US), and JANVIER LABS (France), Thermo Fisher Scientific (US), Danaher Corporation (US), Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Bruker Corporation (US), PerkinElmer (US). Other prominent players include Merck KGaA (Germany), GE Healthcare (US), and Bio-Rad Laboratories (US), genOway (France), Cyagen Biosciences (US), GVK BIO (India), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty Ltd. (Australia), Harbour BioMed (US) among others.
Charles River Laboratories (US) has extensive portfolio of animal models, particularly mice models and services. With more than 70 years of experience, the company has built upon its core competency in the field of in vivo biology through its diverse products and services portfolio. It offers products, services, and solutions that focus specifically on early-stage drug discovery and preclinical development. Its strong portfolio enables it to increase collaboration with clients, from early lead generation to candidate selection. Charles River Laboratories has nearly 90 facilities spread across 20 countries. The company has its presence in the US, Canada, the UK, France, Italy, Spain, the Netherlands, Belgium, Germany, Poland, Ireland, Finland, Luxembourg, Japan, China, India, South Korea, Hong Kong, and Australia.
Geographical Analysis in Detailed:
The global in vivo toxicology market is segmented into North America, Europe, the Asia Pacific, Latin Ametica and Middle East & Africa. In 2019, North America accounted for the largest share of the in vivo toxicology testing market. The large share of the North America region can be attributed to the presence of major players operating in the toxicology market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=105308811
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
